Cryo Cell International Inc (CCEL) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Cryo cell International Inc   (NYSEAMER: CCEL)
    Sector  Healthcare    Industry Healthcare Facilities
   Industry Healthcare Facilities
   Sector  Healthcare

Select the Financial Report: Select the Period:


Description of Cryo Cell International Inc's Business Segments


Cryo-Cell International, Inc. is a leading provider in the field of cord blood and cord tissue banking, as well as other related biobanking services. Their offerings can be categorized into several key segments, products, and services:

1. Cord Blood Banking
a. Private Cord Blood Banking:
- Cryo-Cell provides families the opportunity to store their newborns cord blood for personal use. This involves the collection, processing, and cryopreservation of cord blood stem cells at childbirth, ensuring accessibility for potential future medical treatments.
- Families typically choose this option for various reasons, including the potential for treating genetic disorders, certain types of cancer, and various other medical conditions.

b. Public Cord Blood Banking:
- Cryo-Cell also contributes to public cord blood banks. Families can choose to donate their newborn’s cord blood, which can then be used for research or made available for transplant to patients in need, especially individuals who do not have a suitable matched donor.

Cord Tissue Banking
- In addition to cord blood, Cryo-Cell offers the option to bank umbilical cord tissue. This tissue is rich in mesenchymal stem cells, which have shown potential for treating a variety of medical conditions due to their regenerative properties.
- The collection and storage process is similar to that of cord blood, ensuring that families have access to a rich source of stem cells that could be utilized for future therapeutic purposes.

Stem Cell Services
- Stem Cell Therapy: Cryo-Cell provides information and facilitates access to stem cell therapy opportunities for certain conditions, enhancing the potential use of stored stem cells.
- Research and Development: The company often collaborates with researchers and institutions to explore new therapeutic applications for stem cells derived from cord blood and tissue.

Educational Resources and Support
- Cryo-Cell is committed to informing prospective parents about the benefits and uses of cord blood and tissue banking. They provide educational materials, webinars, and consultations to help families make informed decisions regarding stem cell storage.
- The company offers comprehensive guidance during the process of collection and storage, ensuring parents feel supported throughout the experience.

International Collection and Processing
- Recognizing the global need for stem cell resources, Cryo-Cell has established international partnerships and systems for the collection and preservation of cord blood outside of the United States. This expansion allows families across various regions to access high-quality cord blood banking services.

Quality Assurance and Compliance
- Cryo-Cell adheres to strict regulatory standards and guidelines to ensure the highest quality of service in collection, processing, and storage. This includes compliance with the FDA and AABB (American Association of Blood Banks) requirements, ensuring safety and efficacy in their offerings.

Family Plans and Financing Options
- Cryo-Cell provides various plans tailored to fit different family needs and budgets. This includes flexible payment options and promotional offers to make stem cell banking more accessible for families.
- They may also provide financing plans for families looking to secure long-term health resources without the immediate upfront costs.

Conclusion
Cryo-Cell International, Inc. is dedicated to pushing the boundaries of regenerative medicine through extensive offerings in cord blood and tissue banking. Their emphasis on quality, customer education, and global accessibility underpins their mission to empower families with the future health resources that stem cells represent. As advancements in medical research continue to evolve, Cryo-Cell’s innovative services aim to play a significant role in harnessing the potential of stem cells for various medical applications.


Composition of Cryo cell International Inc Revenues by Segments

 
Umbilical Cord Blood and Cord Tissue Stem Cell Service    99.48 % of total Revenue
PrepaCyte CB    0.5 % of total Revenue
Public Cord Blood Banking    0.02 % of total Revenue

Q1 three months ended (Feb 28 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Umbilical Cord Blood and Cord Tissue Stem Cell Service 7.64 99.48 %
PrepaCyte CB 0.04 0.5 %
Public Cord Blood Banking 0.00 0.02 %
Total 7.68 100 %




Q1 three months ended (Feb 28 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Umbilical Cord Blood and Cord Tissue Stem Cell Service -2.83 % -
PrepaCyte CB 84.55 % -
Public Cord Blood Banking -98.28 % -
Total -3.59 % -75.66 %




Q1 three months ended (Feb 28 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total 0.05 0.61 %




Q1 three months ended (Feb 28 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total -83.35 % -




Annual Report on Cryo cell International Inc Divisions, Sales by Country

 
Umbilical Cord Blood and Cord Tissue Stem Cell Service   Umbilical Cord Blood and Cord Tissue Stem Cell Service Segment contribution to total sales 99.42 % of total Revenue
PrepaCyte CB   PrepaCyte CB Segment contribution to total sales 0.17 % of total Revenue
Public Cord Blood Banking   Public Cord Blood Banking Segment contribution to total sales 0.41 % of total Revenue
Florida   Florida Segment contribution to total sales 3.17 % of total Revenue


Twelve months ended 2025
CCEL s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Umbilical Cord Blood and Cord Tissue Stem Cell Service 31.38 99.42 %
PrepaCyte CB 0.05 0.17 %
Public Cord Blood Banking 0.13 0.41 %
Total 31.57 100 %
Florida 1.00 3.17 %


Twelve months ended 2025
CCEL s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -2.43 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Umbilical Cord Blood and Cord Tissue Stem Cell Service -0.54 % -
PrepaCyte CB -20.3 % -
Public Cord Blood Banking -64.68 % -
Total -1.31 % -
Florida 0 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.